Generation and characterization of MEK and ERK inhibitors- resistant non-small-cells-lung-cancer (NSCLC) cells

BACKGROUND: The RAS/RAF/MEK/ERK pathway is one of the most downregulated pathway in cancer. Inhibitors of RAF and MEK have established clinical use while ERK inhibitors recently faced the clinic. We aimed to generate resistant cell lines which could be helpful for defining new combinations able to o...

Descripción completa

Detalles Bibliográficos
Autores principales: Iezzi, Alice, Caiola, Elisa, Scagliotti, Arianna, Broggini, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6199806/
https://www.ncbi.nlm.nih.gov/pubmed/30352565
http://dx.doi.org/10.1186/s12885-018-4949-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6199806/
https://www.ncbi.nlm.nih.gov/pubmed/30352565
http://dx.doi.org/10.1186/s12885-018-4949-6

Ejemplares similares